INDIA – Aptar Pharma, a division of the US-based Aptar, has inaugurated a new manufacturing facility in Mumbai to bolster its production capabilities in Southeast Asia.
Spanning an area of 7,000 square meters, the new facility resides within the Palava Industrial and Logistics Park at Taloja in Mumbai. It has successfully secured ISO 15378 certification, a testament to its adherence to quality standards.
Aptar Mumbai initially commenced operations in 2012, primarily focusing on assembling and supplying metered dose valves and pumps.
However, its manufacturing scope has now broadened significantly, aimed at enhancing production capacity for pharmaceutical clients in Southeast Asia and delivering more innovative product solutions.
This expansion initiative, initiated in early 2022, echoes Aptar’s commitment to localizing operations. It stands as a direct response to the escalating demand from customers in the region, forming an integral part of the company’s global expansion agenda.
Gael Touya, President of Aptar Pharma, expressed, “The remarkable growth witnessed by our Aptar Pharma business in India underscores the significance of today’s milestone in our investment within the Southeast Asia region.
“Over the past 11 years, Aptar Mumbai has consistently furnished safe, top-quality products, meeting the most stringent regulatory requirements. This new facility marks a pivotal stride in addressing the needs of our regional clientele, ultimately benefiting patients.”
According to Xiangwei Gong, President of Aptar Asia, this new facility will significantly augment local capabilities, empowering the drug delivery system manufacturer to cater to customer demands swiftly and adeptly.
The Mumbai site is anticipated not only to foster local talent but also to bolster the overall expansion plans of the company.
Sanjay Kapote, President of Aptar Southeast Asia Pharma, emphasized, “This new Mumbai site provides a larger footprint, facilitating the expansion of our well-established assembly operations.
Additionally, it enables further localization efforts and supports our vision of introducing additional Aptar Pharma technologies tailored for the Asian market.”
In October, Aptar unveiled intentions to augment capacity in France, the USA, and China. These strategic initiatives are aimed at fortifying the company’s ability to cater to partner needs on a more localized and responsive level.
This approach not only addresses the escalating demand but also foresees future market developments.
Beyond expanding capacity, the company is actively enhancing its capabilities, placing a paramount focus on elevating overall quality standards.
This dual approach—bolstering both capacity and quality—underscores Aptar Pharma’s commitment to advancing its global presence. It solidifies the company’s readiness to effectively address both current and forthcoming market demands.
For all the latest packaging and printing industry news from Africa and the World, subscribe to our NEWSLETTER, follow us on Twitter and LinkedIn, like us on Facebook, and subscribe to our YouTube channel.
